Epigenetic markers as promising prognosticators for bladder cancer

Kim, Young Kyoon; Kim, Wun-Jae

doi:10.1111/j.1442-2042.2008.02143.x

Cited by 60 publications

(53 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Detection of DNA promoter methylation in cancers may be used as a diagnostic, prognostic or surveillance biomarker, especially when the aberrant methylation inactivates tumour suppressor genes. 17,18 The methylation of the promoter region of the CDH13 gene has been reported in several human cancers, including bladder cancer, 12 but the methylation status of CDH13 in serum DNA and its clinical significance for patients with bladder TCC remain unclear.…”

Section: Yl Lin G Sun Xq Liu Et Al Cdh13 Methylation and Bladder Tccmentioning

confidence: 99%

Clinical Significance ofCDH13Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma

Lin

Sun

et al. 2011

J Int Med Res

View full text Add to dashboard Cite

H-cadherin (CDH13; also known as T-cadherin), which functions as a tumour suppressor, is frequently silenced by promoter methylation in human cancers including bladder transitional cell carcinoma (TCC). This study investigated the clinical significance of methylation of the CDH13 gene promoter in serum from patients with bladder TCC. Methylation status of CDH13 in serum samples from 127 patients with primary bladder TCC and 41 healthy volunteers (controls) was examined by methylation-specific polymerase chain reaction. CDH13 methylation was found in 39 patients with bladder TCC (30.7%) but in no controls. CDH13 methylation was significantly associated with advanced tumour stage, high-grade tumour, large tumour size, tumour recurrence and poor prognosis. The results suggested that CDH13 methylation in serum may be a potential predictive biomarker for malignancy in bladder TCC, and an independent pre-therapeutic predictor of outcome. Demonstration of CDH13 methylation in serum may facilitate in the prediction of which patients require more aggressive additional post-operative systemic therapy.

show abstract

Section: Yl Lin G Sun Xq Liu Et Al Cdh13 Methylation and Bladder Tccmentioning

confidence: 99%

Clinical Significance ofCDH13Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma

Lin

Sun

et al. 2011

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…103,106 The most common epigenetic changes studied in bladder tumor markers relate to DNA methylation. 103 Lin et al evaluated the promoter methylation of E-cadherin, p16, p14, and RASSF1A in 57 patients with bladder cancer and found RASSF1A to be the best individual marker, with a sensitivity of 65%, and found the combination of RASSF1A, p14, and E-cadherin to have a sensitivity of detecting bladder cancer of 83%.…”

Section: Tumor Biology and Markersmentioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

299

275

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

show abstract

“…Importantly, promoter methylation events are being recognized for their potential as both diagnostic and prognostic indicators for a variety of malignancies including bladder, prostate, and colon cancers. 12,13 We have previously identified HOXD3 promoter hypermethylation in PCa through a genome-wide CpG island microarray screen of GS 6 and GS 8 cases.…”

mentioning

confidence: 99%

DNA methylation of HOXD3 as a marker of prostate cancer progression

Kron

Liu

Pethe

et al. 2010

Laboratory Investigation

View full text Add to dashboard Cite

DNA methylation in gene promoters causes gene silencing and is a common event in cancer development and progression. The ability of aberrant methylation events to serve as diagnostic and prognostic markers is being appreciated for many cancers, including prostate cancer. Using quantitative MethyLight technology, we evaluated the relationship between HOXD3 methylation and clinicopathological parameters including biochemical recurrence, pathological stage, Gleason score (GS), and Gleason pattern in a series of 232 radical prostatectomies performed between 1998 and 2001. HOXD3 methylation was significantly greater in GS 7 cancers vs GSr6 cancers (P-value o0.001) as well as pT3/pT4 vs pT2 cancers (P-value o0.001). The proportion of cases with high methylation in GS 7 vs rGS 6 and pT3/pT4 vs pT2 were also significantly different (P-values ¼ 0.002 and 0.005, respectively). There were also significant increases in methylation from Gleason pattern 2-3 and from pattern 3 to 4/5 (paired t-test P-values ¼ 0.01 and o0.001, respectively), whereas methylation from lymph node metastases was decreased when compared with matched tumor tissue (P-value ¼ 0.029). HOXD3 methylation was associated with biochemical recurrence in univariate analysis (P-value ¼ 0.043) and showed evidence for interaction with pathological stage as a predictor variable in Cox regression analysis (P-value ¼ 0.028). The results indicate that HOXD3 methylation distinguishes low-grade prostate cancers from intermediate and high-grade ones and may also have prognostic value when considered together with pathological stage.

show abstract

Epigenetic markers as promising prognosticators for bladder cancer

Cited by 60 publications

References 49 publications

Clinical Significance ofCDH13Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma

Clinical Significance ofCDH13Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma

Bladder Cancer in 2010: How Far have We Come?

DNA methylation of HOXD3 as a marker of prostate cancer progression

Contact Info

Product

Resources

About